NewsRoom Articles - Page 32 of 48

ThursdayDec 22, 2022 9:00 am

Luis Merchan, Helping Flora Growth Corp. (NASDAQ: FLGC) Become Global Leader in the CBD Space

Luis Merchan was appointed President of Consumer Goods at Flora in July 2020 before being appointed as the company’s CEO five months later, and chairman of its Board of Directors in May 2022Merchan would lend his years of experience at Macy’s, where he led various sales and marketing initiatives, including the B2B corporate team responsible for bringing in $160 million in annual revenue Under his leadership, Flora has transitioned from the development stage to a full-scale international distributor with operations in over 12 countries worldwide. Mr. Merchan has also spearheaded several M&As, all of which have since set the company up…

ThursdayDec 15, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing the Seizure Treatment Market with Successful EPIL-A21-1 Animal Study

Lexaria has multiple studies planned that will commence early in 2022DehydraTECH increases Lexaria’s ability to leverage multiple markets, including the growing CBD sector, which is expected to meet and exceed $108 billion in revenue by 2027DehydraTECH can increase the efficacy of the drugs being administered, offering faster absorption and lowering the delivery time According to the Epilepsy Foundation, epilepsy is the fourth most common neurological condition globally, affecting one in every 26 people. About 48 out of every 100,000 people are diagnosed with the condition every year, and as of 2019, it affected approximately 50 million people (https://ibn.fm/O0Nms). With the…

WednesdayDec 14, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment

John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarterThe company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023CNS looks to build on the successful patient enrollment and dosing in France, which brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe, as it works toward interim analysis of clinical trials in mid-2023Through…

WednesdayDec 14, 2022 9:45 am

Cepton, Inc. (NASDAQ: CPTN) Remains Committed to Improving Road Safety Through Development of Lidar Solutions for Assisted and Autonomous Driving

Nearly all automotive OEMs have plans to include lidar sensors within their assisted and automated driving platformsGaining public trust in the ability of vehicles to operate safely while providing automated driving features will be a key milestone for widespread adoptionL2+/L3 ADAS is likely to be an enabler as it helps ease the public with broader hands-free functions while maintaining the ability to take over as neededCepton’s lidar sensors are uniquely positioned to benefit from these core industry growth trends and the Company remains committed to delivering superior driving experiences with added safety and convenience Automotive OEMs have made headlines recently…

TuesdayDec 13, 2022 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 2022 Calendar Year in Review

Lexaria Bioscience is a global innovator in drug delivery platforms whose patented DehydraTECH(TM) technology has demonstrated the ability to improve the bioavailability and increase the speed of onset of many drugsIn calendar 2022, the company achieved a number of milestones in various areas, including research programs, receipt of patents, and licensing agreementsLexaria started and completed its fourth and most comprehensive hypertension study yet, investigating the capabilities of DehydraTECH-CBD, with the study showing that its formulation resulted in a sustained reduction in blood pressure over the study period (five weeks)The company has also started investigating DehydraTECH-CBD as a potential therapeutic for…

MondayDec 12, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin

Glioblastoma, also known as GBM, is a fatal and incurable brain cancer that tends to recur aggressively after initial treatmentCNS Pharmaceuticals is a U.S.-based pharmaceutical innovator whose flagship drug candidate, Berubicin, is a potentially pivotal treatment for treating GBM because of its novel apparent ability to cross the blood-brain barrier at effective levelsCNS is building upon prior clinical trial outcomes with its global potentially pivotal trial currently registering patients in the United States and EuropeBerubicin’s development is being advanced with potential time and cost savings thanks to the FDA’s decision to grant it Fast Track and Orphan Drug status The…

MondayDec 12, 2022 9:45 am

Vision Energy Corp. (VENG) Announces Ticker Change and Engages Rho Adviseurs for Planning Services in the Development of Europe’s First Green and Low-Carbon Energy Terminal

Rho Adviseurs has been engaged by Vision Energy, a growing renewable energy facilities developer, to provide specialist studies for environmental impact assessment and policy, process guidance, and spatial planning, all required for the permit applications for Vision’s Green Energy HubVision Energy’s Green Energy Hub is positioned to be the first terminal in Europe focused on green and low-carbon energy products, and located in the North Sea Port of Vlissingen at the mouth of the Westerschelde estuaryVision Energy is focused on governments that support regulatory standards promoting hydrogen production and alternatives to traditional fossil fuels in support of green energy solutions…

SundayDec 11, 2022 9:00 am

Cepton, Inc. (NASDAQ: CPTN) Announces Collaboration with Exwayz, as Lidar is Quickly Becoming an Essential Sensor Technology Within the Robotics Sector

Autonomous robotics are increasingly being used to automate manual logistics processesIn addition to its own software solutions, Cepton collaborates with software provider Exwayz to present a robotic solution for global customersThe company recently announced that it will unveil its upcoming next-generation automotive lidar solution, the Vista-X120 Plus, at the forthcoming CES 2023 event in Las VegasAs part of that product launch, Cepton has been recently recognized as a 2023 Innovation Award honoree by CES within the vehicle tech and advanced mobility category In early June, Amazon unveiled its new fleet of autonomous robots, designed to revolutionize the way that half…

WednesdayDec 07, 2022 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Findings of Animal Anti-Seizure Study Program Suggesting that DehydraTECH(TM)-CBD Is More Effective at Lower Doses and Works More Rapidly than FDA-Approved Epidiolex

Lexaria recently announced the findings of the first two studies from its EPIL-A21-1 animal research programThe program is designed to assess the effectiveness of patented DehydraTECH(TM)-CBD in reducing or eliminating seizure activity compared to Epidiolex, a CBD-based anti-seizure drugThe first study evidenced that DehydraTECH-CBD is more efficacious at lower doses than EpidiolexThe second study demonstrated DehydraTECH-CBD’s enhanced effectiveness; specifically, the formulation acted more rapidly than Epidiolex Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) formulation has demonstrated performance enhancements compared to Epidiolex(R), the first and only FDA-approved CBD medication for…

FridayDec 02, 2022 9:45 am

Vision Energy Corp. (VIHDD) Develops Carbon-Reduced Solutions for Commercial, Industrial, and Transportation Industries, as It Pursues Landmark Design for First European Terminal

The European Green Deal, with the objective to become climate-neutral by 2050, implies a near-total phase-out of fossil fuels in the EU energy systemVision Energy signed a cooperation agreement with Linde Engineering to accelerate efforts for its pioneering Green Energy Terminal in the North Sea Port of Vlissingen, the NetherlandsEngineering efforts under the agreement have commenced and are anticipated to conclude in April 2023, supporting the company’s target to reach a Final Investment Decision by Q3 2023 Hydrogen presents a global opportunity to reduce greenhouse gas emissions due to its high efficiency and zero-or near-zero-emissions operation. The global hydrogen market…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000